Pyxis Oncology, Inc.
NASDAQ:PYXSBiotechnology
+$0.11 today
- Market cap
- $168.65M
- Beta
- 1.43
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$1.29
Volume 0.75M
Average 0.50M
PYXS Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Pyxis Oncology, Inc.NASDAQ: PYXS
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock broadly unchanged from a year ago
Common stock stood at $63K at the end of Q1 FY2026, up 1.6% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at +22.8% a year.
Context
- Common stock amounted to 0.1% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +1.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 63K USD
- Year-over-year change
- +5.0%
- 4-year CAGR
- +18.5%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 63K | +5.0% |
| FY2024 | 2024-12-31 | 60K | +33.3% |
| FY2023 | 2023-12-31 | 45K | +32.4% |
| FY2022 | 2022-12-31 | 34K | +6.3% |
| FY2021 | 2021-12-31 | 32K | — |
Common Stock vs competitors
How PYXS compares with its peers on the latest reported figures
- PYXS's Mar 2026 common stock of $63K is the 4th highest of the 10 companies compared; the peer median is $23K.
- Its year-over-year change of +1.6% is the 8th highest of 10, against a peer median of +28.6%.
- Common stock amounts to 0.1% of total assets for PYXS, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $64.69M | +179666.6% | +34.8% | 0.0% | |
| Mar 2026 | $291K | +36.0% | +1.0% | 0.1% | |
| Mar 2026 | $80K | -5.9% | -2.0% | 0.0% | |
| Mar 2026 | $63K | +1.6% | +22.8% | 0.1% | |
| Mar 2026 | $60K | +9.1% | +15.8% | 0.0% | |
| Mar 2026 | $23K | +43.8% | +26.0% | 0.0% | |
| Mar 2026 | $21K | +31.3% | +44.2% | 0.0% | |
| Mar 2026 | $10K | +11.1% | +14.5% | 0.0% | |
ZURAZura Bio Limited | Mar 2026 | $9K | +28.6% | — | 0.0% |
| Mar 2026 | $6K | +0.0% | +14.5% | 0.0% | |
| Peer median (excluding PYXS) | $23K | +28.6% | +15.1% | 0.0% | |
Competitors are the stored peer set for PYXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 274.74M | 179.29M | 9.66M | 19.47M | 15.42M |
| Short-term Investments | 0 | 0 | 109.63M | 107.46M | 51.44M |
| Net Receivables | 0 | 598K | 21K | 0 | 700K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 1.56M | 5.41M | 4.27M | 4.75M | 4.55M |
| Total Current Assets | 278.67M | 186.61M | 124.6M | 132.44M | 72.11M |
| Property, Plant & Equipment (Net) | 1.24M | 24.77M | 24.81M | 22.14M | 19.42M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 24.31M | 2.6M | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 109K | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 1.35M | 24.77M | 49.12M | 24.74M | 19.42M |
| Total Assets | 280.02M | 211.38M | 173.73M | 157.18M | 91.52M |
| Account Payables | 11.95M | 7.1M | 3.9M | 4.86M | 10.89M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 7.66M | 0 | 0 |
| Other Current Liabilities | 3.23M | 5.33M | 5.58M | 4.63M | 3.75M |
| Total Current Liabilities | 18.71M | 31.63M | 25.76M | 17.68M | 21.13M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 2.16M | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 18.92M | 22.26M | 18.75M | 16.98M |
| Total Liabilities | 18.71M | 50.56M | 48.02M | 36.43M | 38.11M |
| Common Stock | 32K | 34K | 45K | 60K | 63K |
| Retained Earnings | (91.72M) | (212.44M) | (286.23M) | (363.56M) | (443.18M) |
| Accumulated OCI | 0 | 0 | 63K | 170K | 53K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 261.31M | 160.82M | 125.7M | 120.75M | 53.41M |
| Total Debt | 165K | 18.92M | 21.33M | 20.2M | 18.67M |
| Net Debt | (274.57M) | (160.37M) | 11.67M | 727K | 3.25M |
Pyxis Oncology, Inc.
NASDAQ:PYXS
Intrinsic Alpha fair value
Locked
Current Price
$1.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.